These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38320023)

  • 41. Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).
    Callahan M; Amin A; Kaye FJ; Morse MA; Taylor MH; Peltola KJ; Sharma P; O'Reilly EM; Meadows Shropshire S; O'Brien S; Tschaika M; Le DT
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38316517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
    Apolo AB; Powles T; Escudier B; Burotto M; Zhang J; Simsek B; Scheffold C; Motzer RJ; Choueiri TK
    Eur J Cancer; 2022 Dec; 177():63-71. PubMed ID: 36327527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
    Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
    Phillips AL; Reeves DJ
    Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
    Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR
    J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
    van Not OJ; Verheijden RJ; van den Eertwegh AJM; Haanen JBAG; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kamphuis AM; Kapiteijn E; May AM; de Meza MM; Piersma D; van Rijn R; Stevense-den Boer MA; van der Veldt AAM; Vreugdenhil G; Blokx WAM; Wouters MJM; Suijkerbuijk KPM
    JAMA Oncol; 2022 Dec; 8(12):1794-1801. PubMed ID: 36301521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Complete Remission of Metastatic Melanoma of the Scalp Following Treatment With Nivolumab Plus Relatlimab.
    McMinn ME; Brister KA; Orr WS; Sheehan NT; Christopher WO
    Am Surg; 2024 Aug; 90(8):2078-2079. PubMed ID: 38553440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
    Weber JS; Schadendorf D; Del Vecchio M; Larkin J; Atkinson V; Schenker M; Pigozzo J; Gogas H; Dalle S; Meyer N; Ascierto PA; Sandhu S; Eigentler T; Gutzmer R; Hassel JC; Robert C; Carlino MS; Di Giacomo AM; Butler MO; Muñoz-Couselo E; Brown MP; Rutkowski P; Haydon A; Grob JJ; Schachter J; Queirolo P; de la Cruz-Merino L; van der Westhuizen A; Menzies AM; Re S; Bas T; de Pril V; Braverman J; Tenney DJ; Tang H; Long GV
    J Clin Oncol; 2023 Jan; 41(3):517-527. PubMed ID: 36162037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
    Choueiri TK; Powles T; Albiges L; Burotto M; Szczylik C; Zurawski B; Yanez Ruiz E; Maruzzo M; Suarez Zaizar A; Fein LE; Schutz FA; Heng DYC; Wang F; Mataveli F; Chang YL; van Kooten Losio M; Suarez C; Motzer RJ;
    N Engl J Med; 2023 May; 388(19):1767-1778. PubMed ID: 37163623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
    Gettinger SN; Redman MW; Bazhenova L; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Ramalingam SS; Tavernier SS; Yu H; Unger JM; Minichiello K; Highleyman L; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
    JAMA Oncol; 2021 Sep; 7(9):1368-1377. PubMed ID: 34264316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.
    Ossato A; Damuzzo V; Baldo P; Mengato D; Chiumente M; Messori A
    Cancer Med; 2023 Feb; 12(3):2155-2165. PubMed ID: 35920297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
    Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
    Kaseb AO; Hasanov E; Cao HST; Xiao L; Vauthey JN; Lee SS; Yavuz BG; Mohamed YI; Qayyum A; Jindal S; Duan F; Basu S; Yadav SS; Nicholas C; Sun JJ; Singh Raghav KP; Rashid A; Carter K; Chun YS; Tzeng CD; Sakamuri D; Xu L; Sun R; Cristini V; Beretta L; Yao JC; Wolff RA; Allison JP; Sharma P
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):208-218. PubMed ID: 35065057
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
    J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
    J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
    Koseła-Paterczyk H; Rutkowski P
    Expert Opin Biol Ther; 2023 May; 23(5):383-388. PubMed ID: 37200112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.